Literature DB >> 16472137

Na+ channel pharmacology and molecular mechanisms of gating.

K Yamaoka1, S M Vogel, I Seyama.   

Abstract

Electrogenesis of efficiently propagated action potentials requires synchronized opening of transmembrane Na+ channels possessing a sodium selectivity-filter, a high-throughput ion-conductance pathway, and voltage-dependent gating functions. These properties of the Na+ channel have long been the target of molecular analysis. Several toxins and drugs, known to selectively bind to Na+ channels, have been used as pharmacological tools to investigate Na+ channel properties either electrophysiologically or chemically. Recent analyses of the protein crystal structure of bacterial voltage-dependent K+ channels have provided important clues to the identity of mobile structures involved in channel gating. The new information may be applicable to Na+ channels, and may well require a total revision of our understanding of gating mechanisms of sodium channels. Several experiments challenge the emerging view that channel gating by S6 transmembrane segments is triggered by signals from voltage sensors floating in membrane lipid. Herein, we review the various toxin and drug molecules that affect the gating behavior of Na+ channels in this new structural framework, by characterizing the binding sites of these toxins, and assessing the pharmacological effects resulting from changes in the structure of the toxin or sodium channel.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16472137     DOI: 10.2174/138161206775474468

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  5 in total

1.  State-Dependent Modification of Voltage-Gated Sodium Channels by Pyrethroids.

Authors:  David M Soderlund
Journal:  Pestic Biochem Physiol       Date:  2010-06-01       Impact factor: 3.963

2.  Role of eslicarbazepine in the treatment of epilepsy in adult patients with partial-onset seizures.

Authors:  Martin E Brown; Rif S El-Mallakh
Journal:  Ther Clin Risk Manag       Date:  2010-04-15       Impact factor: 2.423

3.  Discovery of potent CLC chloride channel inhibitors.

Authors:  Kimberly Matulef; Andrew E Howery; Li Tan; William R Kobertz; J Du Bois; Merritt Maduke
Journal:  ACS Chem Biol       Date:  2008-07-18       Impact factor: 5.100

4.  Promiscuous binding in a selective protein: the bacterial Na+/H+ antiporter.

Authors:  Raphael Alhadeff; Assaf Ganoth; Miriam Krugliak; Isaiah T Arkin
Journal:  PLoS One       Date:  2011-10-12       Impact factor: 3.240

Review 5.  Clinical utility of eslicarbazepine: current evidence.

Authors:  Gaetano Zaccara; Fabio Giovannelli; Massimo Cincotta; Alessia Carelli; Alberto Verrotti
Journal:  Drug Des Devel Ther       Date:  2015-02-10       Impact factor: 4.162

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.